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ABSTRACT
Objective: The 22-item Unidimensional Fatigue Impact Scale (U-FIS) pro-
vides an index of the impact of fatigue on patients with multiple sclerosis
(MS). The objective is to produce eight new language versions of the
U-FIS: Canadian-English, Canadian-French, French, German, Italian,
Spanish, Swedish, and US-English.
Methods: The U-FIS was translated via two translation panels. Cognitive
debrieﬁng interviews conducted with patients in each country assessed face
and content validity. Scaling and psychometric properties were assessed
via survey data with patients in each country completing the U-FIS, Not-
tingham Health Proﬁle (NHP), and demographic questions.
Results: Cognitive debrieﬁng interviews demonstrated U-FIS acceptabil-
ity. Analysis of postal survey data showed all new language versions to be
unidimensional. Reliability was high, with test-retest correlations and
internal-consistency coefﬁcients exceeding 0.85. Initial evidence of validity
was provided by moderate to high correlations with NHP scales. The
U-FIS was able to discriminate between groups based on employment
status, perceived MS severity, and general health.
Conclusion: The U-FIS is a practical new measure of the impact of fatigue.
It was successfully adapted into eight new languages to broaden availabil-
ity for researchers. Psychometric analyses indicated that the new language
versions were unidimensional and reproducible with promising construct
validity.
Keywords: fatigue, multiple sclerosis, patient reported outcomes, ques-
tionnaire, Rasch, U-FIS.
Introduction
Fatigue is intrinsic to multiple sclerosis (MS) and is the most
commonly reported symptom of the disease [1]. About 75% of
MS patients have persistent or sporadic fatigue [2]. It is usually
deﬁned as a sense of exhaustion, lack of energy or tiredness and
is disabling, disrupts many aspects of daily living and can lead to
unemployment [3,4]. Studies suggest that fatigue is associated
with feelings of loss of control, psychological distress, and pain
[5].
Fatigue is difﬁcult to measure particularly as the symptom
does not correlate highly with measures of fatigability (such as
decline in strength following sustained activity or cognitive
fatigue following tasks requiring sustained attention) [6,7].
Given the apparently limited value of such tests as indicators of
the severity and impact of MS-related fatigue it is important that
patients’ self-reports of their fatigue are collected. Several fatigue
scales are available [8–11]. The quality of these is highly variable
but the best example and most widely used is the Fatigue Impact
Scale (FIS) [12–17]. The FIS has been identiﬁed by the Multiple
Sclerosis Council for Clinical Practice Guidelines “as the most
appropriate for assessing the impact of MS-related fatigue on
quality of life” [18]. The questionnaire taps the fatigue construct
indirectly—asking how patients’ levels of fatigue affect their
ability to undertake activities. The original FIS provides a proﬁle
of three scores: the effects of fatigue on physical, cognitive, and
psychosocial functioning.
A previous study was undertaken to determine a unidimen-
sional questionnaire (the U-FIS) empirically derived from the FIS
in the UK [19]. This scale is valuable as it provides a holistic
index of the impact of fatigue from the patient’s perspective that
can be used in clinical studies and trials. The present article
describes the adaptation and validation of eight new language
versions of the U-FIS (Canadian-English, Canadian-French,
French, German, Italian, Spanish, Swedish, and US English).
Materials and Methods
The adaptation process involved three stages for each new lan-
guage version: translations, assessment of face and content valid-
ity, and evaluation of scaling and psychometric properties.
Patients
Different patient samples were included at each stage of the
study in each country. Participants were recruited via patients’
organizations in the USA. In Italy, patients were recruited
through both patients’ organizations and clinical centers. Where
participants were recruited via patient organizations, they were
required to answer screening questions prior to enrolment to
ensure that they were eligible for the study. For all other lan-
guage versions patients were recruited from clinical centers.
Patients with signiﬁcant comorbidity that might inﬂuence their
responses to the questionnaire, such as diagnosed psychiatric
disorders or cancer, were excluded from the study. All patients
provided informed consent for their participation and patient
conﬁdentiality was maintained at each stage. Where patients
were recruited through clinical centers, ethical approval was
obtained from the relevant research ethics board prior to the
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commencement of study activities. All patients were issued with
a unique identiﬁcation number at the start of study activities. No
personal identifying information was used in connection with
study materials.
Translation
The dual-panel translation methodology was used to produce the
new language versions of the U-FIS [20]. This method focuses on
the production of questionnaires that are conceptually equivalent
to the original version rather than attempting to achieve linguis-
tic or semantic equivalence. The approach involved running two
translation panels (a “professional” translation panel and a
“lay” translation panel) locally in each country. This method
aims to produce quality within the translation process, rather
than checking it a posteriori. The method assumes that the veri-
ﬁcation and acceptability of translations should rest with people
who are typical of the patients who will later be asked to com-
plete the questionnaire. The professional panel comprised a
group of individuals ﬂuent in both the target and source lan-
guage. The panel worked together as a group to agree on the
most appropriate translations. These were then considered by a
group of monolingual local people of average educational attain-
ment (the “lay” panel). The remit of this group was to ensure
that the translations were expressed in natural, everyday lan-
guage. This ensured that the items were understood in the same
way by both the target and source cultures and expressed in a
way that was most appropriate for the target culture. MS
patients were excluded from both panels as the purpose was to
determine the most appropriate wording for the U-FIS rather
than to comment on its content. All panels consisted of between
four and seven participants. Only the lay panel was required for
the US-English and Canadian-English adaptations.
Assessment of Face and Content Validity
Cognitive debrieﬁng interviews were conducted with MS patients
in each country to test the acceptability, understanding, rel-
evance, and comprehensiveness of the new translations. Partici-
pants completed the U-FIS in the presence of an interviewer who
noted any problems experienced by the interviewee. Participants
were then asked to consider the acceptability and appropriate-
ness of the items and whether any important issues had been
omitted.
Scaling and Psychometric Evaluation
Psychometric surveys were conducted in each country to generate
data that would allow the psychometric testing of the question-
naire. In all countries participants completed the U-FIS, demo-
graphic questions and items about perceived MS severity and
general health by postal survey on two occasions, two weeks
apart. Participants in all countries other than Spain also com-
pleted the Nottingham Health Proﬁle (NHP) [21,22].
Questionnaires. The U-FIS includes 22 items measuring the
impact of fatigue (Appendix A). Individuals rate the degree to
which they have been affected by fatigue during the previous
week on a ﬁve-point scale (ranging from “Never” to “All the
time”). Rasch analysis of the original UK U-FIS indicated a
four-point response option (with two responses collapsed) gave
the optimal response scoring. This scoring method was used for
all language versions. Items are summed to give a total score that
can range from 0 to 66. High scores are indicative of greater
impact of fatigue. The UK measure has been shown to have good
reproducibility and validity and to be unidimensional [18].
The NHP is a measure of perceived distress that consists of
six sections: energy level, pain, physical mobility, sleep, social
isolation, and emotional reactions. Each section is scored 0–100
with a high score indicating greater distress.
Data analyses. Rasch analysis [23] was conducted on the data
from each country to determine scale unidimensionality. Statis-
tics indicating ﬁt to the model test how far the observed data
match that expected by the model. Speciﬁcally, item–person inter-
action statistics were considered. These are distributed as a Z
statistic with mean of zero and standard deviation of one (which
indicates perfect ﬁt to the model). An item–trait interaction sta-
tistic reported as a chi-square was also generated to reﬂect the
property of invariance across the trait. A nonsigniﬁcant chi-
square (P > 0.01) would indicate that the U-FIS was unidimen-
sional and that individual item scores could be summed to derive
an overall score. Finally, the person separation index (PSI) was
generated to determine the extent to which items distinguished
between distinct levels of fatigue on the U-FIS scale. A minimum
PSI value of 0.7 was required for group use and 0.85 for indi-
vidual use.
Rasch analysis was also used to assess differential item func-
tioning (DIF). DIF is an additional aspect of model ﬁt and occurs
when subgroups of individuals respond systematically differently
to items, thus having the potential to produce bias within the
scale [24]. While the impact of fatigue might be expected to be
different for certain groups (for example, older persons may have
higher U-FIS scores than younger respondents), their group mem-
bership at any given level of the trait should not inﬂuence how
they score. U-FIS scores were tested for DIF by age (above or
below mean) and gender in the present analyses. Rasch analysis
was conducted using RUMM 2020 (RUMM Laboratory Pty Ltd,
Perth) [25].
Item responses were explored through item-descriptive fre-
quencies to investigate the acceptability of the items. Internal
consistency (the degree of relatedness of items) was assessed by
Cronbach’s alpha coefﬁcients for each scale. A value of 0.70 or
above is indicative of adequate internal consistency [26]. Repro-
ducibility of the new U-FIS scales was assessed using the test-
retest method. Spearman’s rank correlations of the U-FIS scores
at the two administrations were calculated. A high correlation
(above 0.85) indicates that a scale produces an acceptably low
level of random measurement error [27]. Convergent and diver-
gent validity were evaluated by assessing the level of association
(Spearman’s rank correlations) between scores on the U-FIS and
those on the NHP subscales. As fatigue has an impact on many
other impairments and activities experienced by patients it was
expected that there would be moderate correlations between
scores on the two measures. However, it was predicted that the
correlation between U-FIS and NHP Energy level would be
higher because of the similarity of the constructs assessed by the
two scales. Discriminative validity was assessed by examining the
U-FIS scores of respondents who differed according to their
self-rated MS severity (rated mild/moderate/quite severe/severe)
and self-perceived current general health (rated very good/good/
fair/poor). Differences in U-FIS scores were also assessed between
groups split by age (above or below the median) and employment
status (working vs. unable to work because of MS). Nonpara-
metric tests for independent samples (Mann-Whitney U-test for
two groups and Kruskal-Wallis one-way analysis of variance for
three or more groups) were employed. The SPSS 15.0 (SPSS (UK)
Ltd., Woking, Surrey, UK) statistical package was employed for
psychometric analysis.
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Results
Translation
The translation panels generally found that the items were
readily translatable and no serious translation problems were
encountered. The absence of technical terms in the U-FIS aided
the translation process. In each language, there were particular
items that took time and careful consideration to translate. In
some cases the translations were revised by the lay panel while
maintaining the meaning of the original English items.
Face and Content Validity
Interviewee details are shown in Table 1. Overall, participants
reported that the questionnaire was clear and easy to understand.
In all countries participants reported that the measure was rel-
evant to their experience of the impact of fatigue. Respondents
considered that the U-FIS presented a good coverage of their
experience of the impact of fatigue impact and that no important
aspects of their experience had been missed. Individual respon-
dents suggested adding idiosyncratic items. For example, in
Spain; two female respondents suggested that childcare issues
could be included and one additional respondent suggested
including “sadness.” However, no consistent omissions were
identiﬁed.
Scaling and Psychometric Postal Survey
Details of the participants are shown in Table 1.
U-FIS scaling properties. All language versions of the U-FIS ﬁt
the Rasch model (Table 2). Item ﬁt statistics showed that one
item in the Canadian-English (“Been unable to provide emo-
tional support to your family”) and one item in the French
version (“Had to limit your physical activities”) displayed low
P-values indicating misﬁt the Rasch model. After applying Bon-
ferroni corrections, DIF by gender was shown in only one item in
the Swedish version.
Traditional psychometric properties. Throughout this section
questionnaires with missing responses were omitted from the
analyses and tables.
Item frequencies. Item score distributions were good for each
country. No items attracted the same response from all respon-
dents in any language version. In addition, the level of missing
data for each item was low (below 5%) for all languages.
Internal consistency. Cronbach’s alpha coefﬁcients were high in
all language versions indicating good inter-relatedness of items
(Table 3).
Reproducibility (reliability). Test-retest coefﬁcients were good
for all language adaptations, exceeding 0.85 for all languages
(Table 4).
Convergent validity. Correlations between scores on the U-FIS
and the NHP section scores are shown in Table 4. As expected,
Table 1 Demographic details of study participants
Country
C-E C-F F D I E Sw US-E
Cognitive debrieﬁng interviews
n 15 15 9 15 15 11 14 15
Female
n 13 11 5 9 11 5 8 11
% 86.7 73.3 55.6 60.0 73.3 55.6 57.1 73.3
Age (years)
Mean 42.8 39.2 39.0 42.9 51.7 48.9 47.8 54.3
SD 12.9 15.8 12.9 13.4 12.9 8.3 11.5 5.9
Type of MS (n)
Relapsing-remitting 11 8 1 1 3 0 1 8
Primary-progressive 0 2 1 1 9 7 3 1
Secondary-progressive 3 2 2 0 2 3 8 5
Progressive-relapsing 0 0 0 0 0 0 0 1
Benign 0 2 1 0 1 0 0 0
Not reported 1 1 4 13 0 1 2 0
MS duration (years)
Mean 8.7 11.8 12.0 8.4 19.7 19.5 12.4 22.7
SD 6.9 10.0 9.2 11.6 12.3 10.4 6.5 13.7
Postal validation survey
n 96 102 85 76 100 87 167 104
Female
n 71 56 48 54 65 56 102 85
% 74.0 64.4 56.5 71.1 65.0 64.4 61.1 81.7
Age (years)
Mean 44.5 46.1 48.5 42.1 53.1 43.6 48.7 45.7
SD 9.9 10.5 10.4 12.3 12.1 11.0 12.1 10.8
Type of MS (n)
Relapsing-remitting 70 39 12 40 17 41 47 82
Primary-progressive 4 7 17 7 29 6 14 4
Secondary-progressive 5 19 23 9 29 16 25 10
Progressive-relapsing 3 0 6 2 11 2 6 2
Benign 10 8 2 2 4 21 7 2
Not reported 4 29 25 16 10 1 68 10
MS duration (years)
Mean 11.6 10.4 15.3 8.8 17.8 9.0 15.4 10.1
SD 8.5 7.5 9.4 8.0 10.8 7.3 10.1 8.9
C-E, Canada (English); C-F, Canada (French); D, Germany; E, Spain; F, France; I, Italy; Sw, Sweden; US-E, US English; MS, multiple sclerosis.
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results indicated that U-FIS scores were most strongly associated
with NHP Energy Level section scores. This was apparent for all
language versions with the exception of the French version.
There were moderate correlations between scores on the U-FIS
and the other NHP sections. Only one NHP scale (Sleep in the
Italian validation survey) was not statistically signiﬁcantly
related to U-FIS score.
Discriminative validity. There were no signiﬁcant differences in
U-FIS scores according to gender in any of the language versions.
U-FIS scores associated with age, employment, perceived MS
severity, and general health are shown in Table 5. Only the
German version of the U-FIS distinguished between older and
younger patient groups. The former group had signiﬁcantly
higher U-FIS scores (indicating greater impact of fatigue) than
younger patients.
All language versions of the U-FIS, with the exception of the
Italian version, distinguished between participants on the basis of
MS-related inability to work. In all language versions the group
unable to work had higher U-FIS scores. There were statistically
signiﬁcant differences in U-FIS scores between groups on the
basis of both self-reported MS severity and general health.
Respondents rating their MS severity or general health worse had
higher U-FIS scores.
Discussion
The importance of obtaining patients’ views on the efﬁcacy of
their treatment is now well recognized. It is particularly critical
when assessing interventions for chronic diseases such as MS
where treatment is intended to relieve symptoms or slow pro-
gression rather than to cure. Employing patient reported out-
comes as end points in clinical studies and trials provides an
assessment of the patient’s perspective on the beneﬁts of treat-
ment that cannot be gained from clinical outcomes. The impor-
tance of fatigue in MS has been well documented. Research
indicates that fatigue can both exacerbate the impact of MS
symptoms [28] and contribute to a reduction in patients’ life
quality, independent of disease severity [29,30]. The U-FIS was
designed to be an accurate measure of the impact of fatigue on
the lives of MS patients that would also be practical and provide
an index of this impact. Such an index is more easily interpreted
than a proﬁle of scores. The present study has developed eight
new language versions of the U-FIS to enable the measure to be
more widely available to clinical researchers.
The application of the Rasch model demonstrated that each
of the new U-FIS scales was unidimensional, had good item
stability over time and minimal DIF. One item in the French and
one in the Canadian-English adaptations misﬁt the Rasch model.
Further studies are needed to assess whether these misﬁtting
items should be considered consistently problematic. Each of the
new scales also demonstrated high internal consistency and test-
retest reliability, indicating that the U-FIS is suitable for use with
Table 2 Overall ﬁnal ﬁt statistics for the U-FIS (Time 1)
Language version (n)
Item–trait interaction
chi-square P-value PSI
Item–person interaction
Items Persons
Mean SD Mean SD
Canadian–English (92) 0.08 0.97 -0.09 0.91 -0.33 1.57
Canadian–French (99) 0.48 0.95 0.01 0.76 -0.23 1.48
French (84) 0.06 0.96 0.17 1.07 -0.23 1.50
German (72) 0.93 0.97 -0.19 0.87 -0.53 1.69
Italian (98) 0.03 0.95 0.20 1.02 -0.28 1.60
Spanish (79) 0.35 0.95 -0.10 0.90 -0.29 1.51
Swedish (158) 0.60 0.96 -0.28 1.16 -0.48 1.67
US-English (104) 0.13 0.95 -0.04 1.02 -0.55 1.90
PSI, person separation index.
Table 3 Internal consistency and reproducibility of the new language
versions of the U-FIS
U-FIS version
Internal
consistency (n)
Test-retest
reliability* (n)
Canadian-English 0.98 (92) 0.89 (78)
Canadian-French 0.96 (96) 0.86 (95)
French 0.96 (70) 0.89 (55)
German 0.97 (75) 0.92 (69)
Italian 0.96 (83) 0.91 (66)
Spanish 0.95 (75) 0.86 (55)
Swedish 0.97 (148) 0.91 (119)
US English 0.96 (99) 0.88 (90)
*All correlations are signiﬁcant at the 0.01 level (two-tailed).
Table 4 Convergent validity of the new language versions of the U-FIS with the Nottingham Health Proﬁle
Nottingham Health Proﬁle sections
Energy
level (n)
Pain
(n)
Emotional
reactions (n) Sleep (n)
Physical
mobility (n)
Social
isolation (n)
Canadian-English 0.86 (90) 0.50 (91) 0.57 (88) 0.45 (91) 0.61 (89) 0.50 (87)
Canadian-French 0.79 (95) 0.45 (95) 0.57 (93) 0.39 (96) 0.48 (95) 0.49 (95)
French 0.48 (68) 0.42 (67) 0.55 (61) 0.29 (67) 0.25 (65) 0.49 (67)
German 0.74 (75) 0.60 (74) 0.62 (71) 0.49 (74) 0.56 (75) 0.53 (73)
Italian 0.56 (81) 0.39 (71) 0.37 (80) 0.14* (81) 0.54 (75) 0.29 (82)
Swedish 0.75 (148) 0.44 (143) 0.69 (141) 0.32 (145) 0.44 (146) 0.60 (143)
US-English 0.71 (98) 0.50 (97) 0.51 (98) 0.48 (97) 0.52 (98) 0.48 (99)
All correlations are signiﬁcant at the 0.05 level (two-tailed) except where marked with an *.
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individual patients in clinical practice. Correlations with scores
on the NHP supported the convergent validity of the U-FIS.
Discriminative validity was shown by the ability of the U-FIS to
distinguish between groups of patients categorized by employ-
ment status and perceived general health and severity.
The study has a number of limitations. Primarily, as it was
designed to adapt and validate the U-FIS—it did not allow for a
formal assessment of the cross-cultural equivalence of the differ-
ent language versions of the U-FIS. Furthermore, the design of
the study did not allow a comparison of U-FIS scores with
clinical markers of multiple sclerosis or clinical measures of
fatigue. The two-week time interval between questionnaire
administrations was designed to allow the assessment of repro-
ducibility but did not allow the assessment of the responsiveness
of the U-FIS. It is anticipated that further use of the U-FIS will
provide data to enable the assessment of its association with
clinical factors and of its responsiveness to treatment effects. It
should also be noted that there were differences in the country
samples in terms of MS type and duration. However, Rasch
analysis is assumed to be sample independent and so these dif-
ferences should not have compromised study results. Further-
more, sample sizes in the French, German, and Spanish
adaptations were fairly small for the purposes of Rasch analysis.
Larger sample sizes for these countries would be beneﬁcial. It is
concluded that the scaling and psychometric properties of the
new language versions of the U-FIS are highly promising. The
U-FIS should prove to be a valuable tool for assessing the impact
of fatigue on the lives of patients with MS.
The study was funded by Novartis Pharmaceuticals. The authors are
particularly grateful to the MS International Federation for their assistance
and to the many patients who participated in the development and testing
of the U-FIS.
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